Assessment of methylphenidate-induced changes in binding of continuously infused [11C]-raclopride in healthy human subjects: Correlation with subjective effects

Psychopharmacology

Volumn 183, Issue 3, 2005, Pages 322-330

  Udo De Haes, J I ^a   Kortekaas, R ^a   Van Waarde, A ^a   Maguire, R P ^a,b   Pruim, J ^a   Den Boer, J A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b PFIZER INC   (United States)

Author keywords

D2; Neurotransmitter release; PET; Receptor binding; Reward; Striatum

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; METHYLPHENIDATE; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ANXIETY; ARTICLE; BOLUS INJECTION; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DRUG EFFECT; EUPHORIA; FEMALE; HUMAN; MALE; NEUROTRANSMITTER RELEASE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ADOLESCENT; ADULT; BLOOD PRESSURE; CARBON RADIOISOTOPES; FEMALE; HEART RATE; HUMANS; MALE; METHYLPHENIDATE; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RECEPTORS, DOPAMINE D2;

EID: 27844563202     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0193-2     Document Type: Article

References (61)

1. Barrett SP, Boileau I, Okker J, Pihl RO, Dagher A (2004) The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride. Synapse 54:65-71
2. Bergström M, Bohm C, Ericson K, Eriksson L, Litton J (1980) Corrections for attenuation, scattered radiation and random coincidences in a ring detector positron emission transaxial tomograph. IEEE Trans Nucl Sci 27:549-554
3. Berridge KC, Robinson TE (1998) What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28:309-369
4. Booij J, Korn P, Linszen DH, van-Royen EA (1997) Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 24:674-677
5. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de-Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94:2569-2574
6. Camps M, Cortes R, Gueye B, Probst A, Palacios JM (1989) Dopamine receptors in human brain: autoradiographic distribution of D2 sites. Neuroscience 28:275-290
7. Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC, Herscovitch P (1993) Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 13:24-42
8. Carson RE, Breier A, de-Bartolomeis A, Saunders RC, Su TP, Schmall B, Der MG, Pickar D, Eckelman WC (1997) Quantification of amphetamine-induced changes in [11C] raclopride binding with continuous infusion. J Cereb Blood Flow Metab 17:437-447
9. Carson RE (2000) PET physiological measurements using constant infusion. Nucl Med Biol 27:657-660
10. Dagher A (2005) Human dopamine response to drugs and natural rewards. In: Abstract INV37 Brain '05, Vrije Universiteit, Amsterdam, 7-11 June 2005
11. De la Fuente Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ (2001) Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293:1164-1166
12. De la Fuente Fernandez R, Phillips AG, Zamburlini M, Sossi V, Calne DB, Ruth TJ, Stoessl AJ (2002) Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 136:359-363
13. Dewey SL, Smith GS, Logan J, Brodie JD, Fowler JS, Wolf AP (1993) Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13:350-356
14. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85:5274-5278
15. Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, Price JL, Mathis CA (2001) Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 49:81-96
16. 11C)-labelled raclopride, specific dopamine D-2 receptor ligands. J Label Compd Radiopharm 24:931-939
17. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ (1995) Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2:189-210
18. Hernandez L, Lee F, Hoebel BG (1987) Simultaneous microdialysis and amphetamine infusion in the nucleus accumbens and striatum of freely moving rats: increase in extracellular dopamine and serotonin. Brain Res Bull 19:623-628
19. Hurd YL, Ungerstedt U (1989) In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur J Pharmacol 166:251-260
20. Ikemoto S, Panksepp J (1999) The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res Brain Res Rev 31:6-41
21. Ito H, Hietala J, Blomqvist G, Halldin C, Farde L (1998) Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab 18:941-950
22. Janowsky DS, Davis JM (1976) Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms. Arch Gen Psychiatry 33:304-308
23. Joyce PR, Donald RA, Nicholls MG, Livesey JH, Abbott RM (1986) Endocrine and behavioural responses to methylphenidate in depression. Psychol Med 16:531-540
24. Kapur S (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160:13-23
25. Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081-1090
26. Kegeles LS, Zea-Ponce Y, Abi-Dargham A, Rodenhiser J, Wang T, Weiss R, Van-Heertum RL, Mann JJ, Laruelle M (1999) Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans. Synapse 31:302-308
27. Kuczenski R, Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68:2032-2037
28. Kunig G, Leenders KL, Martin-Solch C, Missimer J, Magyar S, Schultz W (2000) Reduced reward processing in the brains of parkinsonian patients. Neuroreport 11:3681-3687
29. Laruelle M, Abi-Dargham A, van-Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RB (1995) SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36: 1182-1190
30. Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, Seibyl JP, Zoghbi SS, Bowers MB, Jatlow P, Charney DS, Innis RB (1997) Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17:162-174
31. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451
32. Leenders KL (2002) Disease process and drug treatments in Parkinson's disease. Eur Neuropsychopharmacol 12:575-580
33. Leyton M, Boileau I, Benkelfat C, Diksic M, Baker G, Dagher A (2002) Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men. Neuropsychopharmacology 27:1027-1035
34. Lidow MS, Goldman-Rakic PS, Rakic P, Innis RB (1989) Dopamine D2 receptors in the cerebral cortex: distribution and pharmacological characterization with [3H]raclopride. Proc Natl Acad Sci U S A 86:6412-6416
35. Marsteller DA, Gerasimov MR, Schiffer WK, Geiger JM, Barnett CR, Borg JS, Scott S, Ceccarelli J, Volkow ND, Molina PE, Alexoff DL, Dewey SL (2002) Acute handling stress modulates methylphenidate-induced catecholamine overflow in the medial prefrontal cortex. Neuropsychopharmacology 27:163-170
36. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M (2003) Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23:285-300
37. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang Y, Simpson N, Ngo K, Van Heertum R, Laruelle M (2001) Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D (2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21:1034-1057
38. McClure SM, Laibson DI, Loewenstein G, Cohen JD (2004) Separate neural systems value immediate and delayed monetary rewards. Science 306:503-507
39. Naranjo CA, Tremblay LK, Busto UE (2001) The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry 25:781-823
40. Oswald LM, Wong DF, McCaul M, Zhou Y, Kuwabara H, Choi L, Brasic J, Wand GS (2005) Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacol (in press)
41. Piccini P, Pavese N, Brooks DJ (2003) Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol 53:647-653
42. Pruessner JC, Champagne F, Meaney MJ, Dagher A (2004) Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. J Neurosci 24:2825-2831
43. Rottenberg DA, Moeller JR, Strother SC, Dhawan V, Sergi ML (1991) Effects of percent thresholding on the extraction of [18F]fluorodeoxyglucose positron emission tomographic region-of-interest data. J Cereb Blood Flow Metab 11:A83-A88
44. Schmidt K, Nolte-Zenker B, Patzer J, Bauer M, Schmidt LG, Heinz A (2001) Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence. Pharmacopsychiatry 34:66-72
45. Schultz W (1998) Predictive reward signal of dopamine neurons. J Neurophysiol 80:1-27
46. Slifstein M, Narendran R, Hwang DR, Sudo Y, Talbot PS, Huang Y, Laruelle M (2004) Effect of amphetamine on [(18)F]fallypride in vivo binding to D(2) receptors in striatal and extrastriatal regions of the primate brain: single bolus and bolus plus constant infusion studies. Synapse 54:46-63
47. Small DM, Jones-Gotman M, Dagher A (2003) Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers. Neuroimage 19:1709-1715
48. Spanagel R, Weiss F (1999) The dopamine hypothesis of reward: past and current status. Trends Neurosci 22:521-527
49. Sun W, Ginovart N, Ko F, Seeman P, Kapur S (2003) In vivo evidence for dopamine-mediated internalization of D2-receptors after amphetamine: differential findings with [3H]raclopride versus [3H]spiperone. Mol Pharmacol 63:456-462
50. Tsukada H, Miyasato K, Kakiuchi T, Nishiyama S, Harada N, Domino EF (2002) Comparative effects of methamphetamine and nicotine on the striatal [(11)C]raclopride binding in unanesthetized monkeys. Synapse 45:207-212
51. Ungless MA (2004) Dopamine: the salient issue. Trends Neurosci 27:702-706
52. Volkow ND, Wang GJ, Fowler JS, Logan J, Schlyer D, Hitzemann R, Lieberman J, Angrist B, Pappas N, MacGregor R, Burr G, Cooper T, Wolf A (1994) Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 16:255-262
53. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Wong C, Hitzemann R, Pappas NR (1999a) Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J Pharmacol Exp Ther 291:409-415
54. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Gifford A, Hitzemann R, Ding YS, Pappas N (1999b) Prediction of reinforcing responses to psychostimulanls in humans by brain dopamine D2 receptor levels. Am J Psychiatry 156:1440-1443
55. Volkow ND, Fowler JS, Wang GJ (2002a) Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 13:355-366
56. Volkow ND, Wang GJ, Fowler JS, Thanos PP, Logan J, Gatley SJ, Gifford A, Ding YS, Wong C, Pappas N (2002b) Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse 46:79-82
57. Volkow ND, Wang GJ, Fowler JS, Molina PE, Logan J, Gatley SJ, Gifford A, Ding YS, Wong C, Pappas NR, Zhu W, Swanson JM (2003) Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology (Berl) 166:264-270
58. Wang G-J, Volkow ND, Hitzemann RJ, Wong C, Angrist B, Burr G, Pascani K, Pappas N, Lu A, Cooper T, Lieberman JA (1997) Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers. Eur Addict Res 3:49-54
59. Wise RA (2004) Dopamine, learning and motivation. Nat Rev Neurosci 5:483-494
60. Zaidi H, Montandon ML, Slosman DO (2004) Attenuation compensation in cerebral 3D PET: effect of the attenuation map on absolute and relative quantitation. Eur J Nucl Med Mol Imaging 31:52-63
61. Zald DH, Boileau I, El-Dearedy W, Gunn R, McGlone F, Dichter GS, Dagher A (2004) Dopamine transmission in the human striatum during monetary reward tasks. J Neurosci 24:4105-4112